October 12 (Wed)
October 13 (Thu)
October 14 (Fri)
| Time | Program | Speaker | Affilliation |
|---|---|---|---|
| 08:00~09:00 | Registration | ||
| 09:00~09:30 | Opening Ceremony | ||
| PL 1 : Continued success of Xcopri development: NDA, subsequent development and commercialization | |||
| 09:30~10:00 | Plenary Lecture 1 | Chair : In-Jin Jang | |
| 09:30~10:00 | Continued success of XCOPRI® development: NDA, subsequent development and commercialization | Jeong-Woo Cho | SK Biopharmaceuticals Co., Ltd. |
| 10:00~10:30 | Coffee Break | ||
| PS 1 Talkshow: Creating global success of drug development in extremely competitive environment | |||
| 10:30~12:00 | Plenary Session 1 | Chair : Hanlim Moon, Hyunsang Muk |
|
| 10:30~12:00 | PS 1 Talkshow: Creating global success of drug development in extremely competitive environment | - - | - |
| 10:30~12:00 | ┗━ Main Panel : Byoungjun Bae(KoNECT) / Panel : Healthcare Discovery - Daekwon Kim(Voronoi), Branden Ryu(BIORCHESTRA) | ||
| 10:30~12:00 | ┗━ Panel : Clinical Development - Seung-Jae Baek(Hanmi Pharm Co. Ltd) , Se-Woong Oh(Yuhan Corporation) / Commercial - Geun-Seog Song(HK inno.N Corp.), Hyeokjae Lee(Celltrion) | ||
| 12:00~13:30 | Lunch | ||
| S1 : Patient-Centric Drug Development & S4 : Drug Delivery to the Target Tissue | |||
| 13:30~15:00 | S1: Patient-Centric Drug Development | Chair : BG Rhee, Yu-Kyeong Hwang |
|
| 13:30~13:50 | Patient-Centric CAR-T Development | Dong-Hyuk Jeon | CUROCELL |
| 13:50~14:10 | Targeting CaV3.1 gene for treating brain disorders | Daesoo Kim | KAIST |
| 14:10~14:30 | Genetic Medicine with Non-viral Delivery Technology | Yoonchul Shin | GenEdit |
| 14:30~14:50 | Open Discussion | ||
| 14:50~15:00 | Q&A | ||
| 15:00~15:30 | Coffee Break | ||
| 15:30~17:00 | S4: Drug Delivery to the Target Tissue | Chair : Jinsan Yoo, Jong-Seo Lee |
|
| 15:30~15:50 | Overcoming the Blood-Brain Barrier for RNA therapeutics | Branden Ryu | BIORCHESTRA Co., Ltd. |
| 15:50~16:10 | Brain Somatic Mutations as RNA Therapeutic Targets in Neurological Disorders | Jeong-Ho Lee | SoVarGen/KAIST |
| 16:10~16:30 | BBB Shuttle by Aptamer Technology | Daekyun Lee | Apatmaer Sciences |
| 16:30~17:00 | Gene Therapy Platform Technologies for the Innovation | Hyun-Bae Jie | Levatio Therapeutics |
| 17:00~17:30 | Open Discussion | ||
| S2 : Creating Comprehensive Drug Development Plan: Strategic Planning through the Product Lifecycle & S5 : Creating Comprehensive Drug Development Plan | |||
| 13:30~15:00 | S2 : Creating Comprehensive Drug Development Plan: Strategic Planning through the Product Lifecycle | Chair : Mi-Young Bahng, Jungshin Park |
|
| 13:30~14:00 | Begin with end in mind: Target product profile and clinical development plan | Nari Yun | GI-Innovation |
| 14:00~14:30 | Orphan Drug and Expedited Drug Development Programs in US/EU | Hye Jin Choi | IQVIA |
| 14:30~15:00 | Global & Market Expansion of K-CAB | Eunji Kim | HK inno.N |
| 15:00~15:30 | Coffee Break | ||
| 15:30~17:00 | S5 : Creating Comprehensive Drug Development Plan: Strategic Planning through Multifunctional Integration | Chair : Myunghoon Kim, Sora Lee |
|
| 15:30~15:50 | Market Segmentation And Multi-Indication Approach | Seung-Won Jeong | Hanall Bio |
| 15:50~16:10 | Clinical Trial Design for Regulatory and Commercial Success | Miyoung Kim | LG Chemical Life Sciences |
| 16:10~16:30 | Biostatistical Validation of Protocol for Clinical and Commercial Success | Sang Joon Lee | Celltrion |
| 16:30~16:45 | How to Incorporate Market Access Strategy to Clinical Trials | Yuri Lee | AMGEN |
| 16:45~17:00 | Q&A and Pannel Discussion | ||
| S3 : Understanding Market and Investment Theory & S6: Practical Investment Guide based on Real Cases | |||
| 13:30~15:00 | S3 : Understanding Market and Investment Theory | Chair : Myungkee Kim | |
| 13:30~13:50 | Global/Korean Life Science Investment Market Trend | Min Sik Shin | KB Investment |
| 13:50~14:10 | Selecting the Right Biotech Company to Invest | Aleum Lee | IMM Investment |
| 14:10~14:30 | Global Life Science Investment Fund | Ted Moon | RM Global |
| 14:30~14:50 | Healthcare Company IPO Trends & Technology Assessment Listing Track Strategies | Wonje Kim | Samsung Securities Co., Ltd |
| 14:50~15:00 | Q&A | ||
| 15:30~17:00 | S6 : Practical Investment Guide based on Real Cases | Chair : Minsik Park | |
| 15:30~16:00 | IPO by Technology Assessment Listing | Jung-Sun Yum | CHA Vaccine Institute |
| 16:00~16:25 | Listing Experiences in the KONEX & KOSDAQ - Genome & Company | Youngjin Seo | Genome & Company |
| 16:25~16:50 | IPO by Special Purpose Acquisition Company (SPAC) | Kisub Lee | Kainos Medicine |
| 16:50~17:00 | Q&A | ||
